Study identifier:D9612R00010
ClinicalTrials.gov identifier:NCT03118778
EudraCT identifier:N/A
CTIS identifier:N/A
Proton Pump Inhibitor (PPI) Inappropriate Use and Economic Burden in Chinese Population: A Descriptive Retrospective Observational Study using Database
Gastrointestinal disease
N/A
No
-
All
90895
Observational
N/A
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: -
Verified 01 Jun 2018 by AstraZeneca
AstraZeneca
-
This is a descriptive retrospective database analysis study in using database. All patients with a physician PPI prescription will be selected to estimate the PPI inappropriate use.
Study primary objective is to identify the inappropriate use of PPI (overall, outpatient & inpatient).
Location
Location
Beijing, China, 100013
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.